Sympathovagal imbalance contributes to progressive worsening of heart failure (HF) and is associated with untoward clinical outcomes. Based on compelling pre-clinical studies that supported the role of autonomic modulation in HF models, a series of clinical studies were initiated using spinal cord stimulation, vagus nerve stimulation, and baroreceptor activation therapy in patients with HF with a reduced ejection fraction. Whereas the phase II studies with baroreceptor activation therapy remain encouraging, the larger clinical studies with spinal cord stimulation and vagus nerve stimulation have yielded disappointing results. Here we will focus on the pre-clinical studies that supported the role of neuromodulation in the failing heart, as well provide a critical review of the recent clinical trials that have sought to modulate autonomic tone in HF patients. This review will conclude with an analysis of some of the difficulties in translating device-based modulation of the autonomic nervous system from pre-clinical models into successful clinical trials, as well as provide suggestions for how to move the field of neuromodulation forward. 
and parasympathetic fibers that convey information from the heart to the central nervous system. The heart also receives afferent parasympathetic input from a series of mechanosensitive nerve endings in large arteries and the carotid sinuses, collectively referred to as baroreceptors, because they are sensitive to changes in blood pressure and blood volume.
The baroreceptors from the carotid arteries have axons in the glossopharyngeal nerve, and those from the aorta have axons that travel in the vagus nerve.
The baroreflex is a major homeostatic mechanism for maintaining blood pressure and is responsible for controlling the afterload of the heart. Baroreceptors are activated by the opening of mechanosensitive ion channels within the sensory terminals, which in turn activate afferent fibers that terminate in the nucleus tractus solitarius in the medulla oblongata. Increased baroreflex activity (e.g., in hypertension) results in a reflex increase in parasympathetic activity that triggers a reflex inhibition of sympathetic tone, thus restoring autonomic balance. Conversely, decreased baroreflex activity (e.g., in hypotension) results in withdrawal of parasympathetic tone that results in a reflex increase in sympathetic tone.
SYMPATHOVAGAL IMBALANCE IN HEART FAILURE
The clinical syndrome of heart failure with a reduced ejection fraction (HFrEF) is associated with sustained activation of the sympathetic nervous system that is accompanied by a withdrawal of parasympathetic tone (2, 4, 5) . Although these disturbances in autonomic control were initially attributed to loss of the inhibitory input from arterial or cardiopulmonary baroreceptor reflexes, there is increasing evidence that excitatory reflexes may also participate in the autonomic imbalance that occurs in HF (2) . Under normal conditions, inhibitory inputs from "high pressure" carotid sinus and aortic arch baroreceptors and the "low pressure" cardiopulmonary mechanoreceptors are the principal inhibitors of sympathetic outflow, whereas discharge from the nonbaroreflex peripheral chemoreceptors and muscle "metaboreceptors" are the major excitatory inputs to sympathetic outflow.
The parasympathetic limb of the baroreceptor heart rate reflex is also responsive to arterial baroreceptor afferent inhibitory input. At rest, healthy individuals display low sympathetic discharge and high rate variability. In HF patients, the peripheral baroreflex responses become suppressed ("blunted") as HF worsens (6) . Blunting of the peripheral arterial and cardiopulmonary baroreceptors results in a derepression of the sympathetic outflow from the central nervous systems and a net increase in efferent sympathetic nerve activity that is accompanied by decreased efferent parasympathetic tone. Consequently, patients with HF have a loss of heart rate variability and increased peripheral vascular resistance (2) .
Dysregulation of the ANS in HF has received considerable attention over the past 3 decades, because of the well-recognized association between increased sympathetic activity and "neurohormonal" activation. Although increased sympathetic stimulation provides short-term support for the cardiovascular system, the sustained activation of the SNS is maladaptive in the long term because it is directly toxic to the heart and circulation and also leads to activation of the renin-angiotensin system, which can also be deleterious to the heart and circulation (reviewed in [7] ). However, the role of the parasympathetic nervous system in the pathophysiology of HF is less well understood. In isolated organ preparations, human in vitro data, and in animal models, local muscarinic receptor stimulation results in inhibition of norepinephrine (NE) release from sympathetic nerve terminals (8, 9) . In vivo, it has been shown that cardiac NE spillover was greater in patients with HF than those with normal LV function, and that infusion with acetylcholine attenuates the amount of NE release in these patients. This effect was not seen in the presence of atropine, suggesting that it is mediated via muscarinic receptor activation (10, 11) . The ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) trial was the first large multicenter clinical study to examine impairment in vagal activity as a prognostic marker following myocardial infarction (MI). ATRAMI enrolled 1,284 post-MI patients and followed them over a 2-year period and showed that patients with depressed baroreflex sensitivity (a marker of decreased vagal activity) had decreased survival (5). The depressed baroreflex sensitivity was also shown to be associated with a worse New York Heart Association (NYHA) functional class and higher mortality in HF patients.
The prognostic value of the depressed baroreflex sensitivity among patients with HFrEF was also observed in the presence of beta-blocker therapy (12, 13) . These observations have led to the development of various device-based therapies that are designed to restore the sympathovagal imbalance in patients with HF.
THERAPEUTIC MODULATION OF THE AUTONOMIC NERVOUS SYSTEM IN HEART FAILURE
It bears emphasis that many of the current therapies for HFrEF patients reverse the sympathovagal imbalance that develops in HF, including pharmacologic therapy with beta-blockers and angiotensinconverting enzyme inhibitors and angiotensinreceptor blockers, exercise training, and cardiac resynchronization therapy (reviewed in [14] ). Despite the tremendous progress in treating patients with HF, the great majority of patients with HF will eventually develop worsening HF (15) . Thus, there continues to be an unmet need for new therapies for treating patients with HF. To this end, there has been growing interest in directly modulating the ANS as a means of counteracting the sympathovagal (17, 18) , as well as decreased inflammation (18) . Indeed, the anti-inflammatory effects of VNS following ischemia and reperfusion injury are accompanied by a reduction in the number of macrophages and apoptotic cells that is paralleled by decreased levels of circulating pro-inflammatory cytokines (19) , which has been referred to as the "cholinergic anti-inflammatory reflex" (20) . Byku and Mann
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revascularization in severe refractory angina, without an increase in ischemic events, suggesting that the improvement in this condition was more complex than the suppression of the nociceptive input associated with myocardial ischemia. SCS applied at the C7 to C8 or T1 to T6 levels ( Figure 2C ) theoretically exerts its effects through activation of ANS, with a resultant overall increase in parasympathetic tone. Byku and Mann
class III HF and an LVEF <40% (41), wherein patients were treated with BAT for 6 months ( Table 3 ). This study showed that there was a significant and sus- Importantly, the duty cycle for VNS for the pivotal INOVATE-HF trial, wherein there was no change in heart rate, was different from the duty cycle used for the CardioFit pilot trial, wherein therein there was a decrease in heart rate. Whether this change in the duty cycle was clinically important and/or explains the disparate outcomes in these 2 trials is not known.
Choosing the proper site of stimulation, strength of stimulation, and duty cycle for SCS is also challenging from the standpoint of designing clinical trials.
Pertinent to this discussion, previous work in dogs has shown that SCS delivered at the T4 level demonstrates a greater antiarrhythmic effect (33) , whereas that at the T1 level is associated with a heightened parasympathetic tone (32) . In the SCS HEART study (35), continuous SCS was performed at the mid-line and left of the mid-line at T1 and T3 levels, whereas intermittent SCS was conducted at mid-line of T2 for T4 levels in the DEFEAT-HF trial (36) . The stimulators in the SCS Heart study were programmed to deliver continuous therapy 24 h/day at 50 Hz, whereas SCS in the DEFEAT-HF trial was for 12 h/day at 50 Hz and was based on individual sleep/ wake cycles. Whether the differences in clinical outcomes in these 2 trials is attributable to the site of stimulation, strength of stimulation, and duty cycle is unknown. Moreover, similar to the problem with VNS in the preceding discussed, it is unclear whether the various protocols that were used in the SCS HEART study and DEFEAT-HF trial were sufficient to restore the proper sympathovagal balance in patients with HF. Viewed together, the observations with regard to the difficulties with VNS and SCS suggest that there is a critical need to be able to perform "dose" response studies that will allow investigators to have a better understanding of the types of stimulation protocols that will be most efficacious. 
